APA (7th ed.) Citation

PJ, N., SB, M., A, G., O, D., DM, C., J, L., . . . T, T. (2022). A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.), 8(1), e12273. https://doi.org/10.1002/trc2.12273

Chicago Style (17th ed.) Citation

PJ, Nathan, et al. "A Phase 1b/2a Multicenter Study of the Safety and Preliminary Pharmacodynamic Effects of Selective Muscarinic M1 Receptor Agonist HTL0018318 in Patients with Mild-to-moderate Alzheimer's Disease." Alzheimer's & Dementia (New York, N. Y.) 8, no. 1 (2022): e12273. https://doi.org/10.1002/trc2.12273.

MLA (9th ed.) Citation

PJ, Nathan, et al. "A Phase 1b/2a Multicenter Study of the Safety and Preliminary Pharmacodynamic Effects of Selective Muscarinic M1 Receptor Agonist HTL0018318 in Patients with Mild-to-moderate Alzheimer's Disease." Alzheimer's & Dementia (New York, N. Y.), vol. 8, no. 1, 2022, p. e12273, https://doi.org/10.1002/trc2.12273.